Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
3.410
+0.070 (2.10%)
At close: Sep 17, 2026, 4:00 PM EDT
3.410
0.00 (0.00%)
Pre-market: Sep 18, 2026, 7:46 AM EDT
Pyxis Oncology Market Cap
Pyxis Oncology has a market cap or net worth of $284.42 million as of September 17, 2026. Its market cap has increased by 123.71% in one year.
Market Cap
284.42M
Enterprise Value
269.26M
1-Year Change
123.71%
Ranking
Category
Stock Price
$3.41
ChartMarket Cap Chart
Since the IPO on October 1, 2021, Pyxis Oncology's market cap has decreased from $523.75M to $284.42M, a decrease of -45.69%. That is a compound annual growth rate of -11.57%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 17, 2026 | 284.42M | 297.22% |
| Dec 31, 2025 | 71.60M | -22.81% |
| Dec 31, 2024 | 92.77M | 16.32% |
| Dec 29, 2023 | 79.75M | 70.77% |
| Dec 30, 2022 | 46.70M | -86.78% |
| Dec 31, 2021 | 353.33M | -32.54% |
| Oct 1, 2021 | 523.75M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Palisade Bio | 294.52M |
| Zentalis Pharmaceuticals | 293.48M |
| Clinuvel Pharmaceuticals | 292.42M |
| Fate Therapeutics | 292.36M |
| Vicore Pharma Holding AB | 291.94M |
| Upstream Bio | 291.93M |
| Fulcrum Therapeutics | 289.17M |
| Immuneering | 287.90M |